Aligned Genetics, Inc. Overview
Aligned Genetics is a small, export-oriented Korean life-science instrumentation company that grew out of Logos Biosystems, a 2008 start-up best known for its LUNA™ family of automated cell counters. It sells under two brands. Logos Biosystems (tagline "Better Tools for Better Science") covers research tools: image-based automated cell counters, bacterial counters, digital and high-content cell imaging systems, and X-CLARITY™ tissue-clearing systems licensed from Stanford's CLARITY technology. Genescale ("Faster Answers for Faster Care") is its molecular-diagnostics brand, aimed at rapid diagnosis at the point of care. The company earns roughly half its revenue from instruments and half from proprietary consumables, which gives it a razor-and-blade recurring stream. Exports account for the large majority of sales; it has US, French and Japanese affiliates and OEM/ODM relationships, including a historical ODM supply arrangement with Olympus and a 2025 OEM contract in China. It is profitable, but growth has slowed sharply since 2023.
What the company does
Aligned Genetics designs, manufactures and sells laboratory instruments and associated consumables for life-science research and bioprocessing, and is building a molecular-diagnostics (MDx) business for clinical use. Its core competence is compact, image-based optical analysis: brightfield and fluorescence imaging, autofocus, and image-analysis software. It applies this to counting and characterising cells (mammalian cells, stem cells, yeast and bacteria), imaging cells in culture, and clearing and imaging whole tissue samples.
The company's own description
The company describes itself on its website as developing innovative technologies and products to open the future of life sciences and molecular diagnostics. It says it is growing two core brands, one for life-science solutions and one for molecular-diagnostic solutions (company website, "Our Brands"). S&P Global's profile, via Simply Wall St, describes the company as offering cellular imaging and biomolecular analysis solutions worldwide, with molecular diagnostics under the Genescale name and imaging and analysis solutions under the Logos Biosystems name.
Independent characterisation
In practice, Aligned Genetics today is overwhelmingly a cell-counter company. The LUNA franchise (LUNA, LUNA-FL, LUNA-II, LUNA-STEM, LUNA-II YF, LUNA-FX7, LUNA-III, LUNA-BX7) and its proprietary counting slides and reagents appear to make up most revenue. That is an inference from the product catalogue, the 50/49 instrument/consumable split, the awards record and the 2025 China OEM deal, all of which centre on cell counters. The company does not publish revenue by product family.
The adjacent businesses are smaller:
Imaging: CELENA® S digital imaging and CELENA® X high-content imaging.
Tissue clearing: X-CLARITY™, a niche neuroscience tool.
Microbial counting: QUANTOM™ / QUANTOM Tx™, notably for microbiome drug manufacturing under GMP.
Emerging projects: SpectraSlide® (2025) and CosmoSort™ cell sorting (a 2024 manufacturing-supply agreement with Meteo Biotech).
The Genescale MDx business has a GMP manufacturing facility (Hanam, 2023) and a Korean MFDS medical-device certification for a molecular-diagnostic instrument (reported September 2026). However, it has not yet produced disclosed, material revenue.
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Product vs. service mix | Instruments about 50%, consumables about 49%, other about 1% (Q2 2026 revenue basis) | Butler (DART-derived segment data) |
| Subscription / licensing | No subscription model disclosed. Historically earned technology fees from ODM contracts (2014 and 2015 ODM agreements with a "global top-tier optical systems company" included technology fees). | Company history |
| Channel | Own brand sold through about 50 distributors in 41 countries (2016) plus direct subsidiaries in the US (2012), France (2016) and Japan (2025); ODM/OEM supply to global and Chinese partners | Sidae (2016); company history |
| Value-chain position | Original equipment manufacturer and brand owner; designs optics, hardware, software and consumables in-house; ODM/OEM supplier to larger instrument brands | Company history; Sidae (2016) |
| Customer types | Academic and government research labs, biopharma R&D, cell and gene therapy and bioprocess developers, microbiome therapeutics manufacturers (QUANTOM Tx under GMP), OEM partners; prospectively hospitals and point-of-care clinical sites (Genescale) | Company history; brand pages |
| End-markets | Life-science research tools (cell counting and analysis, cell imaging, neuroscience tissue clearing), bioprocessing QC, in-vitro diagnostics (molecular) | Company website |
| Geographic orientation | Export-heavy: 97.9% export share in H1 2016 (Sidae); about 86% export in trailing-twelve-month data to Q3 2025 (ValueLine Korea) | See Section 7 |
Strategy
Stated strategic themes
The company's public positioning rests on two pillars:
"Better Tools for Better Science": Logos Biosystems life-science solutions.
"Faster Answers for Faster Care": Genescale molecular diagnostics, aiming to provide faster and more accurate diagnosis at the medical front line.
The IR page states that the company is sustaining domestic and international growth on the basis of its competitiveness. A formal medium-term plan, investor-day materials or numerical guidance are not publicly disclosed in accessible sources.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description / intent |
|---|---|---|
| LUNA-III™ launch and awards | 2024 launch; SelectScience 2025 award | Refresh of the core counter franchise |
| LUNA-BX7™ launch | 2,025 | Top-end counter for bioprocess and cell-therapy customers |
| SpectraSlide® AP-1 launch | 2,025 | Portfolio extension |
| China OEM contract (Shanghai Tech) | 2,025 | Access to the Chinese market via a local OEM brand; full-scale deliveries under way per company news |
| Japan subsidiary | 2,025 | Direct presence in Japan |
| QUANTOM Tx™ GMP adoption | 2,024 | Position in microbiome therapeutics manufacturing QC |
| CosmoSort™ manufacturing supply (Meteo Biotech) | 2,024 | Contract manufacturing; entry into cell sorting |
| National R&D projects | 2,024 | Dogma sequencing, single-cell isolation, laser cell sorter (13 national R&D projects in total, per The VC) |
| Genescale MDx certification | Sep 2026 | First MFDS medical-device certification for the MDx instrument; precondition for clinical sales in Korea |
| Headquarters relocation | 2,026 | Facility consolidation (rationale not disclosed) |
| Share cancellation and treasury share disposal | May–Sep 2026 | Capital management (purpose of the disposal not disclosed) |
| Attendance at 10x Genomics user group annual event | Recent (company news headline) | Engagement with the single-cell genomics ecosystem, consistent with "Genetics" positioning |
ESG and cost programmes
None disclosed.
Financial targets and guidance
None publicly disclosed. The last known numerical forecast was at the 2016 IPO: break-even in 2016 and KRW 1.9 bn operating profit in 2017 (Sidae). Subsequent results (KRW 2.2–3.3 bn operating income in FY2021–FY2025) indicate that the company did reach sustained profitability.
Products & Services
Launch years are from the company history. Detailed specifications and list prices are not publicly disclosed in accessible sources; capability descriptions reflect company and press characterisations only.
Logos Biosystems — Automated cell counters (LUNA™ family)
| Product | Launch | Description / capability | Target customer |
|---|---|---|---|
| LUNA™ | 2,012 | First-generation image-based automated cell counter | Research labs (cell culture) |
| LUNA-FL™ | 2,013 | Dual-fluorescence automated cell counter (viability via fluorescent staining) | Labs needing fluorescence-based viability, e.g. primary cells |
| LUNA-II™ | 2,014 | Autofocusing brightfield automated cell counter | General cell-culture labs |
| LUNA-STEM™ | 2,014 | Counter positioned for stem-cell applications | Stem-cell and regenerative-medicine labs |
| LUNA-II YF™ | 2,016 | Yeast counter | Fermentation, brewing and yeast research |
| LUNA-FX7™ | 2,020 | Advanced automated cell counter; SelectScience "Best New Life Sciences Product 2020" | Bioprocessing, cell and gene therapy |
| LUNA-III™ | 2,024 | Latest brightfield counter; SelectScience Best New Life Sciences Product 2025 | General research and bioprocess labs |
| LUNA-BX7™ | 2,025 | Newest high-end counter (specifications not disclosed) | Bioprocess and advanced cell-therapy users (inferred from the FX7 lineage) |
| ODM/OEM counters | 2015 onward | Counters built for partner brands, e.g. Olympus R1 (2015); Shanghai Tech OEM contract (2025) | Partner brands' customers |
| Counting slides and reagents | Ongoing | Proprietary disposable counting slides/chips (European patent for the counting microchip, 2017) and stains | Installed base (recurring revenue) |
Logos Biosystems — Microbial counting
| Product | Launch | Description | Target customer |
|---|---|---|---|
| QUANTOM™ | 2,016 | Automated bacterial/microbial cell counter | Microbiology and probiotics labs |
| QUANTOM Tx™ | About 2023–24 (designated Innovative Product in 2024) | Automated bacterial cell counter; adopted under GMP by a European microbiome drug developer | Live biotherapeutics and microbiome manufacturers; probiotic QC |
Logos Biosystems — Cell imaging
| Product | Launch | Description | Target customer |
|---|---|---|---|
| CELENA® S | 2,015 | Digital cell imaging system (brightfield/fluorescence benchtop imager) | Cell-biology labs |
| CELENA® X | 2,018 | High-content imaging system | Drug discovery, cell-based assays |
| SpectraSlide® AP-1 | 2,025 | New slide-based product (specifications not disclosed) | Research labs |
| CTC enumeration system | Joint development agreed 2017 with Clinomics | Automated circulating tumour cell enumeration imaging system; commercial status not disclosed | Oncology research / clinical |
Logos Biosystems — Tissue clearing (neuroscience)
| Product | Launch | Description | Target customer |
|---|---|---|---|
| X-CLARITY™ Tissue Clearing System | 2,015 | Automated electrophoretic tissue clearing based on Stanford's CLARITY technology | Neuroscience and 3D tissue imaging labs |
| X-CLARITY™ Polymerization System | 2,016 | Hydrogel polymerisation instrument for the CLARITY workflow | Same |
| X-CLARITY™ Tissue Clearing System II | 2,018 | Second-generation clearing system | Same |
| DeepLabel™ Antibody Staining Kit | 2,019 | Reagent for antibody penetration into cleared tissue (built on KBRI technology transfer, 2018) | Same |
| Clearing reagents | Ongoing | Four reagent types were on sale in 2016 (Sidae) | Same |
Cell sorting
| Product | Year | Description |
|---|---|---|
| CosmoSort™ | 2024 manufacturing-supply agreement with Meteo Biotech | Cell sorter manufactured and supplied under contract. National R&D projects in 2024 covered a laser cell sorter and single-cell isolation (The VC). Commercial details not disclosed. |
Genescale — Molecular diagnostics
| Product | Year | Description |
|---|---|---|
| Genescale molecular-diagnostic instrument | MFDS medical-device certification, September 2026 | Rapid molecular-diagnostic platform ("Faster Answers for Faster Care"), manufactured at the Hanam GMP facility. Model name, assay menu and specifications are not publicly disclosed. |
| COVID-19 saliva self-antigen test | 2021 (Russian MoH registration) | Antigen (not molecular) self-test registered in Russia; current status not disclosed |
Pricing model
Instruments are sold outright, and consumables (slides, reagents) generate recurring pull-through revenue. List prices are not publicly disclosed.
Financial Narrative
Income statement
Source: Butler (DART-derived), annual results in units of KRW 100 m, converted. Growth rates and margins are calculated from these rounded figures. Butler reports FY2025 revenue growth as +1.5% and operating income as −12.1% on unrounded data.
Revenue CAGR, FY2021–FY2025: (16.0 / 11.8)^(1/4) − 1 ≈ 7.9% (calculated).
Gross profit, EBITDA, pre-tax income, EPS and dividends per share are not available as a five-year series from accessible sources:
Quarterly / trailing revenue trajectory: notes and sources
Source: ValueLine Korea: TTM revenue peaked at Q3 2025 and has since declined, which implies Q4 2025 and Q1 2026 were each weaker than the same quarters a year earlier. H1 2026 results (half-year report filed 14 Aug 2026) could not be retrieved in detail.
Balance sheet
A full balance sheet series is not available from accessible sources. Indicative data:
Simply Wall St's summary assessment is an "excellent balance sheet with proven track record". This is a qualitative aggregator rating, not filing data.
Cash flow
Operating cash flow, capex, free cash flow, dividends paid and buybacks are not publicly disclosed in accessible sources. Known capital-allocation events:
-
2018: equity investment in Biogentec (31.8%; amount not disclosed).
-
2021–2023: capex on the Hanam production site and MDx GMP facility (amount not disclosed).
-
2026: headquarters relocation (cost not disclosed).
-
May–September 2026: share cancellation and treasury share disposal (amounts not disclosed).
-
No dividends paid.
Commentary on trends, inflections and drivers
Revenue. Revenue rose from KRW 11.8 bn (FY2021) to KRW 16.0 bn (FY2025), a 7.9% CAGR, but the growth profile has decayed steadily: +16.9% (FY2022), +10.1% (FY2023), +3.9% (FY2024), about +1.3–1.5% (FY2025). TTM revenue then fell to KRW 15.7 bn by Q1 2026. For context, the company had only KRW 4.1 bn of revenue in 2015 (Sidae), so the business roughly quadrupled between 2015 and 2025 before plateauing. The plateau coincides with the well-documented post-pandemic downturn in biopharma and academic tools spending (2023–2025), which hit cell-culture instrument demand industry-wide. It also coincides with intensifying price competition in entry-level cell counters. The 2025 China OEM contract and the LUNA-III / LUNA-BX7 launches are the visible levers for re-acceleration, but their effect is not evident in data through Q1 2026.
Profitability. Operating margin peaked at 21.7% in FY2023 and compressed to 15.0% in FY2025, with operating income down from KRW 3.3 bn to KRW 2.4 bn. With revenue roughly flat, the compression points to rising operating costs: R&D for MDx and new LUNA models, overseas subsidiary build-out (Japan, 2025), and GMP facility overheads. The TTM gross margin of about 69% (to Sep 2025) is high for an instrument maker. That reflects the consumables-rich mix and in-house optics and software.
Net income volatility. Net income has repeatedly diverged from operating income: KRW 5.5 bn in FY2021 versus KRW 2.2 bn operating income, and KRW 4.1 bn in FY2024 versus KRW 2.8 bn. This indicates material non-operating items. Plausible items include financial income on cash balances, valuation changes on financial assets, equity-method results from Biogentec, FX gains on USD/EUR receivables given the export mix, and tax effects. The specific items are not disclosed in accessible sources, so net income should not be extrapolated as a run-rate.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Brand Details
| Brand | Scope | Main products |
|---|---|---|
Logos Biosystems | Life-science research tools | LUNA™ cell counters, QUANTOM™ bacterial counters, CELENA® imaging systems, X-CLARITY™ tissue clearing, DeepLabel™ reagents, counting slides and consumables, SpectraSlide® |
Genescale | Molecular diagnostics (point of care / rapid) | Molecular-diagnostic instrument (MFDS-certified September 2026) and related assays; product names and specifications not publicly disclosed |
Product Type Details
| Product type | Share of revenue, Q2 2026 (%) |
|---|---|
Instruments (장비) | 50 |
Consumables (소모품) | 49 |
Other | 1 |
Revenue by Segment
| Metric | TTM Mar-2025 | TTM Jun-2025 | TTM Sep-2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 16.50 | 17.17 | 17.35 |
Domestic revenue (KRW Bn) | 2.08 | 2.18 | 2.35 |
Export revenue (KRW Bn) | 14.42 | 14.98 | 14.99 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Country | Function | Year | Ownership |
|---|---|---|---|---|
Aligned Genetics, Inc. | Korea | Parent; R&D, manufacturing, headquarters | 2008 | Listed |
Logos Biosystems, Inc. | USA | Sales and service subsidiary | 2012 | Not publicly disclosed (described as a subsidiary) |
Logos Biosystems SARL | France | European sales subsidiary | 2016 | Not publicly disclosed (described as a subsidiary) |
Japan branch/subsidiary | Japan | Sales | 2025 | — |
Biogentec (바이오젠텍) | Korea | IVD developer (blood and molecular diagnostics); Korea University Hospital spin-off | Investment in 2018 | 31.8% at the time of investment (2018); current stake not publicly disclosed |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 11.8 | 13.8 | 15.2 | 15.8 | 16.0 |
Operating income (KRW Bn) | 2.2 | 2.8 | 3.3 | 2.8 | 2.4 |
Net income (KRW Bn) | 5.5 | 2.3 | 3.2 | 4.1 | 2.9 |
Revenue growth YoY (%) | — | 16.9 | 10.1 | 3.9 | 1.3 |
Operating margin (%) | 18.6 | 20.3 | 21.7 | 17.7 | 15.0 |
Net margin (%) | 46.6 | 16.7 | 21.1 | 25.9 | 18.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Metric | Status |
|---|---|
Gross profit (annual) | Not publicly disclosed in accessible sources. TTM to 30 Sep 2025: revenue KRW 17.4 bn, cost of revenue KRW 5.4 bn, gross profit KRW 12.0 bn, gross margin 69.0% (Simply Wall St / S&P) |
EPS (basic/diluted) | Not publicly disclosed as an annual series. TTM EPS: KRW 197 (Investing.com, Aug 2026); KRW 329 (Investing.com, Sep 2026). The figures differ by period. |
Dividends per share | Nil (dividend yield 0.00%, StockHub; none disclosed by Butler) |
Income Statement
| Metric | TTM Mar-2025 | TTM Jun-2025 | TTM Sep-2025 | TTM Dec-2025 | TTM Mar-2026 |
|---|---|---|---|---|---|
Revenue TTM (KRW Bn) | 16.50 | 17.17 | 17.35 | 16.01 | 15.73 |
Financial Analysis — Total assets
| Item | Value | Source / note |
|---|---|---|
Total assets | Not publicly disclosed (accessible sources) | — |
Cash & equivalents | Not publicly disclosed (accessible sources) | Historically strong liquidity: in 2018, Hankyung's quant screen ranked the company in the top 0.21% of the market on quick ratio |
Total debt | Not publicly disclosed. A Simply Wall St headline describes debt as being used "safely"; The VC records one convertible bond issue (amount and date not disclosed) | Simply Wall St; The VC |
Book equity (implied) | About KRW 39.2 bn (Butler: KRW 35.3 bn market cap ÷ 0.90 P/B) or about KRW 33.1 bn (StockHub: KRW 35.8 bn ÷ 1.08 P/B) | Implied from aggregator multiples, not from filings; the two sources differ |
Treasury shares | 0.32% of share count (October 2026) | Butler |
Financial Analysis — ROE
| Ratio | Value | Source / note |
|---|---|---|
ROE | 11.8% (Butler, Oct 2026); 7.39% (ValueLine, Jun 2026); 6.42% (StockHub, Oct 2026) | Sources differ by period and method |
ROA | 6.8% (Simply Wall St summary metric) | Aggregator; period TTM to Sep 2025 |
Current ratio | Not publicly disclosed; liquidity historically very high (2018 quick-ratio ranking) | — |
Debt/equity | Not publicly disclosed; aggregator describes debt as well covered | — |
Net debt/EBITDA | Not publicly disclosed (likely net cash) | — |
P/E (TTM) | 7.60 (Butler); 9.24 (StockHub); 15.67 (ValueLine, Jun 2026); 16.97 (StockHub EN, earlier date) | Varies with price date and TTM period |
P/B | 0.90 (Butler); 1.08 (StockHub); 1.16 (ValueLine, Jun 2026) | — |
Revenue by Region and Revenue by Region (%)
| Region | TTM Mar-2025 | TTM Jun-2025 | TTM Sep-2025 |
|---|---|---|---|
Domestic Korea (KRW Bn) | 2.08 | 2.18 | 2.35 |
Export (KRW Bn) | 14.42 | 14.98 | 14.99 |
Export share (%) | 87.4 | 87.3 | 86.4 |
Export Share by Period
| Period | Export share (%) | Source |
|---|---|---|
H1 2016 | 97.9 | Sidae (IPO coverage) |
TTM Sep-2025 | 86.4 | ValueLine Korea (calculated) |
Revenue by Region
| Metric | 2014 | 2016 | 2020 | 2022 |
|---|---|---|---|---|
Export Tower threshold achieved (USD Mn) | 1 | 3 | 5 | 7 |
Share Price and Market Valuation
| Metric | 2018-07-02 | 2026-03-20 | 2026-06-25 | 2026-08-05 | 2026-09-27 | 2026-10-13 |
|---|---|---|---|---|---|---|
Share price (KRW) | 14,950 | — | 3,075 | 2,900 | 2,965 | 2,520 |
Market cap (KRW Bn) | 48.7 | 65.2 | 43.5 | 41.2 | 42.2 | 35.8 |
Share Price & Returns
| Period | Return | Source |
|---|---|---|
1-year to 27 Sep 2026 | −11.2% | Investing.com |
1-year to 5 Aug 2026 | −16.5% | Investing.com |
3-year | A Simply Wall St article headline reports a 29% gain over three years; its date is not shown, so this is not current | Simply Wall St |
5-year | Not publicly disclosed in accessible sources | — |
52-week range | KRW 2,380 – 6,050 | Investing.com; StockHub |
Price position | About 4% of the 52-week range (13 Oct 2026) | StockHub |
Valuation Multiples
| Multiple | Aligned Genetics | Source |
|---|---|---|
P/E (TTM) | 7.60 (Butler) / 9.24 (StockHub) | Oct 2026 |
P/B | 0.90 (Butler) / 1.08 (StockHub) | Oct 2026 |
EV/Sales | Not computable (net cash/debt not disclosed); price/sales about 2.2x (KRW 35.3 bn market cap ÷ KRW 15.73 bn TTM revenue, calculated) | Calculated |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends; yield 0.00% |
Treasury share disposal | Decision in June 2026 (amended 30 Jun); completed per the 3 Sep 2026 report. |
Treasury shares held | 0.32% (Oct 2026) |
Analyst Conclusions
Management guidance and consensus
There is no public guidance and no consensus estimates.
Bull case
-
The China OEM and MDx launch restart growth. The 2025 Shanghai Tech OEM contract with full-scale deliveries, plus the September 2026 MFDS certification of the Genescale instrument manufactured in the 2023 Hanam GMP facility, are two concrete new revenue channels on a small KRW 16 bn base. Modest wins would move the growth rate visibly.
-
A quality franchise at a deep value multiple. The company has five consecutive years of operating profit, about 69% gross margin and 49% consumables revenue, yet trades at about 0.9–1.1x book and 7.6–9.2x trailing earnings, near its 52-week low.
-
Premium bioprocess positioning. LUNA-FX7 and BX7, award-winning LUNA-III, and the QUANTOM Tx GMP adoption tie the company to the structurally growing cell and gene therapy and live biotherapeutic QC markets, where validated instruments are sticky.
Bear case
-
Structural maturity of the core business. Growth has decayed every year since FY2022, to about 1.5%, and TTM revenue was declining into 2026. Cell counters face entrenched giants and low-end price competition.
-
Margin erosion and non-recurring earnings. Operating margin fell from 21.7% to 15.0% over two years. Reported net income repeatedly depends on non-operating items, so the low P/E may overstate sustainable earnings power.
-
MDx is a costly late entry. Eight years after the 2018 Biogentec investment, Genescale has only just received domestic certification and faces Seegene, SD Biosensor and other incumbents. Spending could continue to dilute margins without commensurate revenue.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | What to watch |
|---|---|
| Q3 2026 quarterly report (due around mid-November 2026) | Whether TTM revenue stabilises above KRW 15.7 bn; operating margin trajectory |
| FY2026 annual report (around March 2027) | Full-year growth, R&D spend, subsidiary results, customer concentration, Biogentec carrying value |
| China OEM volumes | Disclosure of order sizes or a China revenue line |
| Genescale commercialisation | First hospital or clinic placements, assay approvals, reimbursement status, CE-IVDR filings |
| Capital allocation | Further share cancellations or buybacks; any dividend initiation; use of treasury share disposal proceeds |
| Insider transactions | Follow-up filings after the June 2026 ownership report |
| Product cycle | LUNA-BX7 adoption; any FDA/GMP-oriented software validation packages |
| FX | KRW/USD and KRW/EUR moves affecting reported revenue and non-operating income |
Analyst verdict
Aligned Genetics is a niche life-science instrument maker with real but small competitive strengths, now at a strategic inflection. Its core LUNA cell-counter franchise is genuinely well regarded. The evidence is a string of SelectScience awards culminating in the 2025 Best New Product award for LUNA-III, a historical ODM relationship with Olympus, and a fresh OEM deal in China. The economics are attractive: roughly 69% gross margins and half of revenue from consumables. The company has also been profitable at the operating level every year from FY2021 to FY2025.
The financial trajectory, however, has turned. Revenue growth fell from about 17% in FY2022 to about 1.5% in FY2025, and trailing revenue declined into 2026. Operating margin compressed by almost seven percentage points in two years. Net income has been flattered by non-operating gains in several years, so headline P/E ratios of 7.6–9.2x likely understate the true multiple on recurring earnings. The market has noticed: the share price fell by more than half from its 52-week high and now sits near the bottom of its range, at roughly book value.
The investment question therefore turns on whether the two new legs, China OEM volume and Genescale molecular diagnostics, can offset maturity in the core business. The September 2026 MFDS certification is a necessary, but far from sufficient, step into a fiercely contested Korean MDx market. With no guidance, no analyst coverage, thin liquidity and limited English-language disclosure, visibility is poor.
On balance, Aligned Genetics screens as a low-expectation, asset-backed micro-cap with optionality rather than a demonstrated growth story. The next two quarterly prints (Q3 2026 and FY2026) are decisive. Stabilisation of trailing revenue above about KRW 16 bn, together with evidence of China and MDx revenue, would support a re-rating. A further decline would confirm a value trap. Investors should obtain the DART annual and half-year reports to verify balance-sheet strength, cash flow and ownership before drawing firm conclusions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Background | Compensation |
|---|---|---|---|
Jung Yeon-cheol (정연철) | CEO and representative director | Led the IPO and the 2018 Biogentec diagnostics investment; prior roles and education not publicly disclosed in accessible sources | Not publicly disclosed. Korean rules require individual pay disclosure only above KRW 500 m. |
Other C-suite (CFO, CTO, etc.) | — | Not publicly disclosed in accessible sources | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Largest shareholder (presumed CEO and related parties) | Not publicly disclosed in accessible sources | — |
Historical VC investors | KDR (2012), Partners Investment (2014), Suprema Investment (2016); current holdings not disclosed | Company history |
Institutional top-10 | Not publicly disclosed; institutional ownership of KOSDAQ micro-caps is typically minimal | — |
Treasury shares | 0.32% | Butler |
Competitive Landscape
Competitors by Segment
| Product area | Competitor | Competing products (illustrative) | Relative positioning of Aligned Genetics |
|---|---|---|---|
Automated cell counters | Thermo Fisher Scientific (USA) | Countess™ series | Thermo dominates on brand and channel; Logos competes on image quality, fluorescence and price, with strong SelectScience reviews |
Automated cell counters | Bio-Rad Laboratories (USA) | TC20™ | Mid-market rival |
Automated cell counters / bioprocess | Beckman Coulter (Danaher, USA) | Vi-CELL™ BLU | Incumbent in GMP bioprocess; LUNA-FX7/BX7 target the same users |
Automated cell counters | Revvity (Nexcelom, USA) | Cellometer® | Direct image-based rival in fluorescence counting |
Automated cell counters | ChemoMetec (Denmark) | NucleoCounter® | Strong in cell and gene therapy QC |
Automated cell counters | DeNovix (USA), Corning (USA), Olympus/Evident (Japan) | CellDrop™; Corning counter; Evident R1 (originally a Logos ODM product) | Low-to-mid tier; the Evident relationship is both partner and competitor |
Cell imaging / high-content | Molecular Devices (Danaher), Revvity, Agilent (BioTek), Sartorius, Thermo Fisher | ImageXpress®; Operetta®/Opera®; Cytation™; Incucyte®; CellInsight™ | CELENA is a small player against large incumbents |
Tissue clearing | LifeCanvas Technologies (USA), Miltenyi Biotec (Germany) | SmartBatch+; clearing workflows | X-CLARITY was first to market; niche competition |
Molecular diagnostics (point of care / rapid) | Cepheid (Danaher), Seegene, SD Biosensor, Bioneer, Gene System (진시스템) | GeneXpert®; Seegene platforms; Gene System's rapid PCR (UF-340) | Genescale is pre-revenue against entrenched local and global platforms |
Peer Comparison FY2024
| Metric | Aligned Genetics | Thermo Fisher | Danaher | Bio-Rad |
|---|---|---|---|---|
Revenue, FY2024 | KRW 15.8 bn (about USD 0.012 bn) | About USD 42.9 bn | About USD 23.9 bn | About USD 2.6 bn |
Revenue growth, FY2024 | +3.9% | Roughly flat | Roughly flat to down | Roughly down low single digits |
Operating margin, FY2024 | 17.7% | Not compiled | Not compiled | Not compiled |
R&D intensity | — | Not compiled | Not compiled | Not compiled |
“—” = not publicly disclosed.



